Pooled VTE events per 100 patient cycles by treatment modality using random-effects models
| Treatment cohort . | Pooled VTE events/patient-cycle . | Pooled VTE events/100 patient-cycles . | 95% CI . | 3-mo VTE risk, % . | 6-mo VTE risk, % . |
|---|---|---|---|---|---|
| All patients treated with lenalidomide | 0.007685 | 0.77 | 0.48-1.12 | 2.3 | 4.5 |
| Single-agent lenalidomide | 0.0109 | 1.09 | 0.49-1.94 | 3.2 | 6.4 |
| Lenalidomide + biologics | 0.00486 | 0.49 | 0.17-0.97 | 1.5 | 2.9 |
| Lenalidomide + chemotherapy | 0.00891 | 0.89 | 0.39-1.60 | 2.6 | 5.2 |
| Treatment cohort . | Pooled VTE events/patient-cycle . | Pooled VTE events/100 patient-cycles . | 95% CI . | 3-mo VTE risk, % . | 6-mo VTE risk, % . |
|---|---|---|---|---|---|
| All patients treated with lenalidomide | 0.007685 | 0.77 | 0.48-1.12 | 2.3 | 4.5 |
| Single-agent lenalidomide | 0.0109 | 1.09 | 0.49-1.94 | 3.2 | 6.4 |
| Lenalidomide + biologics | 0.00486 | 0.49 | 0.17-0.97 | 1.5 | 2.9 |
| Lenalidomide + chemotherapy | 0.00891 | 0.89 | 0.39-1.60 | 2.6 | 5.2 |